<DOC>
	<DOCNO>NCT02323230</DOCNO>
	<brief_summary>This phase 2 study design ass efficacy safety DPX-Survivac plus low dose cyclophosphamide subject recurrent diffuse large B-cell lymphoma ( DLBCL ) eligible transplant .</brief_summary>
	<brief_title>A Study DPX-Survivac Vaccine Therapy Patients With Recurrent Survivin-expressing DLBCL</brief_title>
	<detailed_description>A multi-center treatment study assess efficacy safety immunotherapeutic vaccine ( DPX-Survivac ) combine low dose cyclophosphamide . Subjects measurable , histologically proven DLBCL express survivin treat open-label , single arm study . Survivin protein commonly over-expressed many type cancer , include DLBCL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Main Subjects histologically proven recurrent DLBCL . Subjects may recurrence primary second treatment regimens DLBCL . Subjects recurrence least 90 day postautologous stem cell transplantation ( ASCT ) eligible . Patients partial response measurable disease first line therapy ( candidate ASCT ) second line therapy without disease progression may also eligible . Previous localize surgery , radiotherapy , chemotherapy 21 day prior SD0 . Subjects may receive previous course investigational biologic therapy include active passive immunotherapy ( e.g . rituximab ) , B cell deplete antibody therapy , radioimmunotherapy ( e.g . tositumomab ibritumomab ) last administration great 77 day prior SD0 . Subjects must least one measurable site disease . Willing undergo pretreatment posttreatment tumor biopsy . Subjects must evidence survivin expression pretreatment tumor sample . A screening Eastern Cooperative Oncology Group Performance Status ( ECOG ) 01 . A life expectancy &gt; 6 month . Main Patients eligible possible curative therapy ASCT . Patients undergoing concurrent chemotherapy , radiation therapy , immunotherapy currently investigational product/trial exclude . There must least 21 day since completion prior chemotherapy/radiation least 77 day since completion immunotherapy study treatment begin ( SD0 ) . Subjects must recover acute toxicity prior treatment ; peripheral neuropathy must &lt; grade 2 . Lactate dehydrogenase ( LDH ) great 2 time upper limit normal . Patients refractory disease last treatment ( i.e . progression within 90 day ) . Patients receive prior survivin base vaccine . Progressive CNS lymphoma require treatment within 84 day prior SD0 . History active autoimmune disease , restrict , inflammatory bowel disease , systemic lupus erythematosus , ankylose spondylitis , scleroderma , multiple sclerosis require treatment within last two year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>